Bat virome

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Friday, July 30, 2021 - 11:56am

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

JBS Couros launches antiviral leather

Thursday, July 22, 2021 - 7:00pm

SÃO PAULO, July 22, 2021 /PRNewswire/ -- JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19. At processing stage, a silver microparticle additive is added to the leather coating   providing it with antiviral qualities.

Key Points: 
  • SO PAULO, July 22, 2021 /PRNewswire/ --JBS Couros has announced the launch of JBS V-Block technology, which inactivates the SARS-Cov-2 virus, the cause of Covid-19.
  • At processing stage, a silver microparticle additive is added to the leather coating providing it with antiviral qualities.
  • "Our leather has undergone scientific tests that prove the inactivation of the SARS-Cov-2 virus.
  • "The use of this technology increases the contact surface of silver and its prominence in the leather, enabling antiviral action," says researcher Lucio Freitas, who participated in the tests of the new material.

US COVID-19 Surveillance Needs an Urgent Boost, Says AHF

Tuesday, July 20, 2021 - 12:18am

New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.

Key Points: 
  • New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.
  • The most common strain of the virus is the highly infectious Delta variant, but the US is falling behind other developed countries in tracking and identifying new strains.
  • SARS-CoV-2 is highly prone to genetic variation as it replicates and spreads across different populations.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005833/en/

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Wednesday, July 14, 2021 - 7:00am

Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.
  • The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the genetic material of the pathogen causing COVID-19.
  • This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic, said Jan Verstreken, Hologics group president, International.
  • Hologic, The Science of Sure, Aptima, and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

Tuesday, July 13, 2021 - 1:00pm

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.

Key Points: 
  • By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.
  • The Phase I study is a randomized, double-blind and placebo-controlled, single and multiple ascending dose study.
  • The easy-to-use nasal spray could be helpful in protecting at-risk populations, such as the elderly or patients with chronic respiratory diseases.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

SaNOtize’s Anti-Viral Treatment Made Available in Israeli Pharmacies

Thursday, July 8, 2021 - 1:00pm

Enovid was granted an emergency use authorization as a medical device by Israels Ministry of Health earlier this year.

Key Points: 
  • Enovid was granted an emergency use authorization as a medical device by Israels Ministry of Health earlier this year.
  • Enovid releases a small dose of nitric oxide (NO), a natural nanomolecule with proven anti-microbial properties including against SARS-CoV-2, the virus that causes COVID-19.
  • SaNOtize is also pleased to announce the appointments of Dan Suesskind and Elaine Campbell to its Board of Directors.
  • The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Thursday, July 1, 2021 - 12:05am

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • A group of 3,975 healthcare personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 nasal swab testing from December 14, 2020, to April 10, 2021.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

Tuesday, June 29, 2021 - 11:00am

Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.

Key Points: 
  • Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.
  • The proposed transaction has been approved by the boards of Pardes Biosciences and FS Development Corp. II, including all of their disinterested directors.
  • Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the worlds most pressing public health challenges.
  • The companys lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.

PERFORMACIDE® Kills Virus Causing COVID-19 In Just 30 Seconds

Tuesday, June 22, 2021 - 3:00pm

Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.

Key Points: 
  • Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.
  • To prove efficacy, PERFORMACIDE was tested directly against the SARS-CoV-2 (COVID-19) virus.
  • CEO and President, Peter Dornau, commented, "Killing the virus that causes COVID-19 in under a minute will dramatically expand the markets for PERFORMACIDE and its sub-registered brands.
  • Mr. Dornau concluded, "PERFORMACIDE already reduces the many steps involved in a full cleaning routine by eliminating rinsing or wiping again.

Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials

Tuesday, June 1, 2021 - 6:30am

Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.

Key Points: 
  • Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.
  • In a preclinical experiment using a CPE (cytopathic effect assay), balixafortide demonstrated strong and robust activity against SARS-CoV-2 (COVID-19) infection at clinically relevant concentrations with no adverse cytotoxic effects.
  • In an in vivo hamster animal model, balixafortide showed positive and statistically significant reduction of viral load of SARS COV-2.
  • Balixafortide also reduced COVID19-relevant inflammation markers in the lung including ISG15 gene expression, a key player of respiratory failure in viral infections.